Tesamorelin — Indexed Studies

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Ellis RJ, Vaida F, Hu K et al.

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Russo SC, Ockene MW, Arpante AK et al.

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Rahman F, McLaughlin T, Mesquita P et al.

Approach to the Patient With Lipodystrophy.

Fourman LT, Grinspoon SK

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Stanley TL, Fourman LT, Wong LP et al.

Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.

Stanley TL, Fourman LT, Zheng I et al.

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Fourman LT, Billingsley JM, Agyapong G et al.

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Fourman LT, Stanley TL, Zheng I et al.

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley TL, Fourman LT, Feldpausch MN et al.

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Adrian S, Scherzinger A, Sanyal A et al.

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Braun LR, Feldpausch MN, Czerwonka N et al.

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons DR, Miller S, Mamputu JC

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC et al.

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO et al.

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO et al.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J et al.

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Makimura H, Murphy CA, Feldpausch MN et al.

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

Friedman SD, Baker LD, Borson S et al.

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Glesby MJ, Albu J, Chiu YL et al.

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura H, Feldpausch MN, Rope AM et al.

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Baker LD, Barsness SM, Borson S et al.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C et al.

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Makimura H, Stanley TL, Chen CY et al.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC et al.

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar T, Mechanic O, Fehmie DA et al.

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy.

Mateo MG, Gutiérrez MDM, Domingo P

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D et al.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC et al.

Therapeutic trial of growth hormone releasing factor in HIV patients.

Winslow DL

Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.

Berger D

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC et al.

Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Brown TT

Effects of growth hormone-releasing factor in HIV-infected patients.

Malgarini RB, Pimpinella G

Manipulation of the growth hormone axis in patients with HIV infection.

Blackman MR

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K et al.

Side effects and complications. Tesamorelin--results from Phase III.

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Falutz J, Allas S, Kotler D et al.

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

Uçaktürk E, Nemutlu E

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Mihalache A, Volfson E, Huang R et al.

Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.

Chege BM, Mwangi PW, Githinji CG et al.

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Thomas A, Walpurgis K, Thevis M

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Cristea CD, Radu M, Toboc A et al.

Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways.

Fourman LT, Stanley TL, Ockene MW et al.

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

Thomas A, Thilmany S, Hofmann A et al.

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

Coppieters G, Deventer K, Polet M et al.

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Memdouh S, Gavrilović I, Ng K et al.

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Fourman LT, Stanley TL, Billingsley JM et al.

Tesamorelin improves fat quality independent of changes in fat quantity.

Lake JE, La K, Erlandson KM et al.

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Pont L, Alechaga É, Terrero A et al.

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

Chisholm TS, Kulkarni SS, Hossain KR et al.